Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET
Company Participants
Bruce C. Cozadd – Co-Founder, Chairman & CEO
Jack Spinks – Corporate Participant
Philip L. Johnson – Executive VP & CFO
Renee D. Gala – President & COO
Robert Iannone – Executive VP, Chief Medical Officer and Global Head of Research & Development
Conference Call Participants
Akash Tewari – Jefferies LLC, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Andrea R. Newkirk – Goldman Sachs Group, Inc., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Basma Mahmoud Radwan Ibrahim – Leerink Partners LLC, Research Division
David A. Amsellem – Piper Sandler & Co., Research Division
David Timothy Hoang – Deutsche Bank AG, Research Division
Gary Jay Nachman – Raymond James & Associates, Inc., Research Division
Jason Matthew Gerberry – BofA Securities, Research Division
Jessica Macomber Fye – JPMorgan Chase & Co, Research Division
Joon So Lee – Truist Securities, Inc., Research Division
Joseph John-Charles Thome – TD Cowen, Research Division
Michael H. Riad – Morgan Stanley, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Operator
Good day, and thank you for standing by. Welcome to Jazz Pharmaceuticals 2025 Second Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker today, Jack Spinks, Executive Director of Investor Relations.
Jack Spinks
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its second quarter 2025 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors should also refer to the press release we issued earlier today that is available on our website.
On the call today are Bruce Cozadd, Chairman and
#Jazz #Pharmaceuticals #plc #JAZZ #Earnings #Call #Transcript